{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["21(1)"],"submitter":["Langedijk AC"],"funding":["Pfizer Inc. Ahuva Averin, Erin Quinn, and Mark Atwood are employees of Avalere Health"],"pubmed_abstract":["The European Medicines Agency has authorized two interventions to prevent lower respiratory tract disease due to respiratory syncytial virus (RSV-LRTD) in infants: nirsevimab, a monoclonal antibody, and bivalent stabilized prefusion F subunit maternal vaccine (RSVpreF). In the Netherlands, RSV-LRTD protection is recommended for all infants with nirsevimab given preferential recommendation over RSVpreF. We evaluated cost-effectiveness of various intervention strategies to prevent RSV in the Netherlands. We employed a cohort model to evaluate clinical and economic outcomes associated with RSV-LRTD during the first year of life among infants receiving RSVpreF with complementary nirsevimab and, alternatively, nirsevimab alone versus no intervention. Model inputs, based principally on Dutch dat"],"journal":["Human vaccines & immunotherapeutics"],"pagination":["2521912"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12934181"],"repository":["biostudies-literature"],"pubmed_title":["Cost-effectiveness of immunization strategies to protect infants against respiratory syncytial virus in the Netherlands."],"pmcid":["PMC12934181"],"pubmed_authors":["Langedijk AC","Quinn E","Smit L","van den Boer J","Averin A","Mendes D","Harteveld L","van den Dungen F","Atwood M","van Houten M","Law A"],"additional_accession":[]},"is_claimable":false,"name":"Cost-effectiveness of immunization strategies to protect infants against respiratory syncytial virus in the Netherlands.","description":"The European Medicines Agency has authorized two interventions to prevent lower respiratory tract disease due to respiratory syncytial virus (RSV-LRTD) in infants: nirsevimab, a monoclonal antibody, and bivalent stabilized prefusion F subunit maternal vaccine (RSVpreF). In the Netherlands, RSV-LRTD protection is recommended for all infants with nirsevimab given preferential recommendation over RSVpreF. We evaluated cost-effectiveness of various intervention strategies to prevent RSV in the Netherlands. We employed a cohort model to evaluate clinical and economic outcomes associated with RSV-LRTD during the first year of life among infants receiving RSVpreF with complementary nirsevimab and, alternatively, nirsevimab alone versus no intervention. Model inputs, based principally on Dutch dat","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-07-16T21:37:53.354Z","creation":"2026-07-10T03:16:02.873Z"},"accession":"S-EPMC12934181","cross_references":{"pubmed":["40561047"],"doi":["10.1080/21645515.2025.2521912"]}}